News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Immunomedics, Inc. (IMMU) Says 90 Y-Clivatuzumab Tetraxetan in Combo With Low-Dose Gemcitabine Active


10/23/2013 8:00:28 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Immunomedics, Inc. (Nasdaq: IMMU [FREE Stock Trend Analysis]), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today reported that multiple cycles of therapy with the Company's pancreatic cancer therapeutic, clivatuzumab tetraxetan labeled with yttrium-90 (^90Y), in combination with low-dose gemcitabine, produced a median overall survival (OS) of more than 5 months in patients with metastatic pancreatic cancer who had received at least 2 prior treatments.

Help employers find you! Check out all the jobs and post your resume.

Read at News Release
Read at Street Insider
Read at News Release


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES